2022
Immunotherapy After Chemotherapy and Radiation for Clinical Stage III Lung Cancer
Pichert MD, Canavan ME, Maduka RC, Li AX, Ermer T, Zhan PL, Kaminski M, Udelsman BV, Blasberg JD, Park HS, Goldberg SB, Boffa DJ. Immunotherapy After Chemotherapy and Radiation for Clinical Stage III Lung Cancer. JAMA Network Open 2022, 5: e2224478. PMID: 35925606, PMCID: PMC9353596, DOI: 10.1001/jamanetworkopen.2022.24478.Peer-Reviewed Original ResearchMeSH KeywordsAgedCarcinoma, Non-Small-Cell LungCohort StudiesFemaleHumansImmunotherapyLung NeoplasmsMaleNeoplasm StagingConceptsStage III non-small cell lung cancerNon-small cell lung cancerClinical stage III non-small cell lung cancerUnresectable stage III non-small cell lung cancerPropensity-matched sampleGeneral US populationSurvival advantageCohort studyLung cancerMultivariable Cox proportional hazards modelsUS populationStage III lung cancerMedian age 66 yearsCox proportional hazards modelNational Cancer DatabaseEfficacy of immunotherapyAge 66 yearsProtocol rangesCell lung cancerClinical trial populationsProportional hazards modelTerms of ageImmunotherapy initiationImmunotherapy recipientsImmunotherapy useChanges in Prostate-Specific Antigen Testing Relative to the Revised US Preventive Services Task Force Recommendation on Prostate Cancer Screening
Leapman MS, Wang R, Park H, Yu JB, Sprenkle PC, Cooperberg MR, Gross CP, Ma X. Changes in Prostate-Specific Antigen Testing Relative to the Revised US Preventive Services Task Force Recommendation on Prostate Cancer Screening. JAMA Oncology 2022, 8: 41-47. PMID: 34762100, PMCID: PMC8587214, DOI: 10.1001/jamaoncol.2021.5143.Peer-Reviewed Original ResearchConceptsProstate cancer screeningUS Preventive Services Task ForcePSA testingCancer screeningInterrupted time series analysisCohort studyUS Preventive Services Task Force (USPSTF) recommendationDraft statementLarge national cohort studyEligible beneficiariesPSA testing ratesRetrospective cohort studyRate of PSANational cohort studyProstate-specific antigenAge-adjusted ratesTask Force recommendationsUSPSTF guidelinesMedian ageGuideline changesProstate cancerMedian numberMAIN OUTCOMEClaims dataTesting rates
2021
Adoption of New Risk Stratification Technologies Within US Hospital Referral Regions and Association With Prostate Cancer Management
Leapman MS, Wang R, Park HS, Yu JB, Sprenkle PC, Dinan MA, Ma X, Gross CP. Adoption of New Risk Stratification Technologies Within US Hospital Referral Regions and Association With Prostate Cancer Management. JAMA Network Open 2021, 4: e2128646. PMID: 34623406, PMCID: PMC8501394, DOI: 10.1001/jamanetworkopen.2021.28646.Peer-Reviewed Original ResearchConceptsProstate magnetic resonance imagingMagnetic resonance imagingHospital referral regionsProportion of patientsProstate cancerGenomic testingCohort studyReferral regionsRetrospective cohort studyProstate cancer carePatient-level analysisCommercial insurance claimsProstate cancer managementUS hospital referral regionsYears of ageProportion of menPatients 40Definitive treatmentCancer careTesting uptakeHRR levelMAIN OUTCOMECancer managementPatientsRegional uptake
2020
Revisiting the Radiation Therapy Oncology Group 1221 Hypothesis: Treatment for Stage III/IV HPV-Negative Oropharyngeal Cancer
Jacobs D, Torabi SJ, Park HS, Rahmati R, Young MR, Mehra S, Judson BL. Revisiting the Radiation Therapy Oncology Group 1221 Hypothesis: Treatment for Stage III/IV HPV-Negative Oropharyngeal Cancer. Otolaryngology 2020, 164: 1240-1248. PMID: 33198564, DOI: 10.1177/0194599820969613.Peer-Reviewed Original ResearchConceptsNational Cancer DatabaseHPV-negative oropharyngeal cancersChemoradiation therapyOverall survivalCancer DatabaseOropharyngeal cancerHPV-negative oropharyngeal squamous cell carcinomaLarge national cancer databaseNeck cancer-specific survivalOropharyngeal squamous cell carcinomaCox proportional hazards regressionKaplan-Meier survival analysisCancer-specific survivalImproved overall survivalMultivariable Cox regressionRetrospective cohort studyAdjuvant chemoradiation therapyUse of surgeryEnd Results ProgramProportional hazards regressionSquamous cell carcinomaSEER cohortAdjuvant therapyCohort studySEER databasePrimary Treatment Selection for Clinically Node-Negative Merkel Cell Carcinoma of the Head and Neck
Jacobs D, Olino K, Park HS, Clune J, Cheraghlou S, Girardi M, Burtness B, Kluger H, Judson BL. Primary Treatment Selection for Clinically Node-Negative Merkel Cell Carcinoma of the Head and Neck. Otolaryngology 2020, 164: 1214-1221. PMID: 33079010, DOI: 10.1177/0194599820967001.Peer-Reviewed Original ResearchConceptsNode-negative Merkel cell carcinomaLymph node evaluationImproved overall survivalPrimary tumor excisionMerkel cell carcinomaCase volumeOverall survivalSurgical managementCell carcinomaTumor excisionTreatment selectionNode evaluationCox proportional hazards regressionGuideline-recommended carePrimary treatment selectionNational Cancer DatabaseNode-negative diseasePercentage of patientsRetrospective cohort analysisInitial surgical managementKaplan-Meier analysisWide local excisionProportional hazards regressionRates of receiptInitial managementTemporal Trends in Opioid Prescribing Patterns Among Oncologists in the Medicare Population
Jairam V, Yang DX, Pasha S, Soulos PR, Gross CP, Yu JB, Park HS. Temporal Trends in Opioid Prescribing Patterns Among Oncologists in the Medicare Population. Journal Of The National Cancer Institute 2020, 113: 274-281. PMID: 32785685, PMCID: PMC7936059, DOI: 10.1093/jnci/djaa110.Peer-Reviewed Original ResearchConceptsOpioid-prescribing ratesOpioid prescribingOpioid Prescribing PatternsOpioid-prescribing guidelinesUS opioid epidemicPalliative care providersMultivariable negative binomial regressionNoncancer populationsPrescribing patternsPrescribing ratesSymptom managementCancer survivorsOpioid epidemicDrug claimsCare providersMedicare populationMedicare beneficiariesPrescribingOncologistsNononcologistsNegative binomial regressionOpioidsBinomial regressionPatientsAnnual number
2019
Multi-institutional analysis of stereotactic body radiation therapy for operable early-stage non-small cell lung carcinoma
Kann BH, Verma V, Stahl JM, Ross R, Dosoretz AP, Shafman TD, Gross CP, Park HS, Yu JB, Decker RH. Multi-institutional analysis of stereotactic body radiation therapy for operable early-stage non-small cell lung carcinoma. Radiotherapy And Oncology 2019, 134: 44-49. PMID: 31005223, DOI: 10.1016/j.radonc.2019.01.027.Peer-Reviewed Original ResearchConceptsNon-small cell lung carcinomaStereotactic body radiation therapyProgression-free survivalEarly-stage non-small cell lung carcinomaOperable patientsBody radiation therapyCell lung carcinomaOverall survivalLocal failureLung carcinomaRadiation therapyInoperable early stage non-small cell lung carcinomaDefinitive stereotactic body radiation therapyLack of resectionPoor surgical candidacyRetrospective cohort studyKaplan-Meier methodologyHigher overall survivalDisease-related outcomesMulti-institutional analysisDocumentation of patientsStandard of careMulti-institutional studyCohort studyInoperable patients
2018
Stereotactic body radiotherapy with adjuvant systemic therapy for early-stage non-small cell lung carcinoma: A multi-institutional analysis
Kann BH, Miccio JA, Stahl JM, Ross R, Verma V, Dosoretz AP, Park HS, Shafman TD, Gross CP, Yu JB, Decker RH. Stereotactic body radiotherapy with adjuvant systemic therapy for early-stage non-small cell lung carcinoma: A multi-institutional analysis. Radiotherapy And Oncology 2018, 132: 188-196. PMID: 30391106, DOI: 10.1016/j.radonc.2018.10.017.Peer-Reviewed Original ResearchConceptsNon-small cell lung carcinomaStereotactic body radiotherapyAdjuvant systemic therapyEarly-stage non-small cell lung carcinomaSystemic therapyMulti-institutional analysisCell lung carcinomaOverall survivalST patientsBody radiotherapyLung carcinomaDefinitive stereotactic body radiotherapyEarly-stage NSCLC patientsClinical risk factorsRetrospective cohort studyKaplan-Meier methodHigher T stageTreatment of patientsMulti-institutional databasePropensity-score matchingPlatinum doubletsST cohortST regimenCohort studyNSCLC patientsAssociation Between Radiation Dose and Outcomes With Postoperative Radiotherapy for N0-N1 Non–Small Cell Lung Cancer
Wang EH, Corso CD, Park HS, Chen AB, Wilson LD, Kim AW, Decker RH, Yu JB. Association Between Radiation Dose and Outcomes With Postoperative Radiotherapy for N0-N1 Non–Small Cell Lung Cancer. American Journal Of Clinical Oncology 2018, 41: 152-158. PMID: 26523443, DOI: 10.1097/coc.0000000000000245.Peer-Reviewed Original ResearchMeSH KeywordsAcademic Medical CentersAgedCarcinoma, Non-Small-Cell LungCohort StudiesDatabases, FactualDisease-Free SurvivalDose-Response Relationship, RadiationFemaleHumansLung NeoplasmsMaleMargins of ExcisionMiddle AgedMultivariate AnalysisNeoplasm InvasivenessNeoplasm StagingPneumonectomyPrognosisProportional Hazards ModelsRadiotherapy DosageRadiotherapy, AdjuvantRadiotherapy, Intensity-ModulatedRetrospective StudiesSurvival AnalysisTreatment OutcomeConceptsNon-small cell lung cancerPostoperative radiotherapyCell lung cancerIntensity-modulated radiation therapyPORT doseOverall survivalLung cancerRadiation therapyUse of PORTNational Cancer Data BaseStage IIProportion of patientsGroup of patientsProportional hazards regressionEvidence of benefitSurgical resectionWorse survivalMultivariable analysisHazards regressionRetrospective studyConformal radiationPatientsRadiotherapy techniquesRadiation modalitiesModern treatment
2017
Angiotensin receptor blockade: a novel approach for symptomatic radiation necrosis after stereotactic radiosurgery
Chowdhary M, Okwan-Duodu D, Switchenko JM, Press RH, Jhaveri J, Buchwald ZS, Zhong J, Chapman BV, Bindra RS, Contessa JN, Park HS, Yu JB, Decker RH, Olson JJ, Oyesiku NM, Abrams RA, Shu HG, Curran WJ, Crocker IR, Patel KR. Angiotensin receptor blockade: a novel approach for symptomatic radiation necrosis after stereotactic radiosurgery. Journal Of Neuro-Oncology 2017, 136: 289-298. PMID: 29124649, PMCID: PMC5784434, DOI: 10.1007/s11060-017-2652-0.Peer-Reviewed Original ResearchConceptsSymptomatic radiation necrosisOverall survivalStereotactic radiosurgeryIntracranial efficacyRadiation necrosisKaplan-Meier methodLate radiation toxicitySignificant predictive factorsArteriovenous malformation patientsCumulative incidence modelsIntracranial outcomesBaseline characteristicsBlockade therapyBrain metastasesProspective trialABT groupConsecutive patientsMedian ageMeier methodPreclinical evidencePredictive factorsAVM cohortsRadiation toxicityPrognostic analysisMultivariate analysisAdjuvant Therapy Use and Survival in Stage II Endometrial Cancer
Lester-Coll NH, Young MR, Park HS, Ratner ES, Litkouhi B, Damast S. Adjuvant Therapy Use and Survival in Stage II Endometrial Cancer. International Journal Of Gynecological Cancer 2017, 27: 1904-1911. PMID: 28763364, DOI: 10.1097/igc.0000000000001095.Peer-Reviewed Original ResearchConceptsReceipt of chemotherapyEndometrioid endometrial carcinomaNational Cancer Data BaseImproved overall survivalRole of chemotherapyOverall survivalAdjuvant chemotherapyAdjuvant treatmentStage II endometrial cancerCox proportional hazards regressionPropensity scoreAdjuvant therapy useGrade 3 diseaseStage II patientsProportional hazards regressionWorse overall survivalMultivariable logistic regressionKaplan-Meier estimatesLog-rank testAdjuvant radiotherapyExcellent prognosisLymphovascular invasionObservational cohortEEC patientsEndometrial cancerPatterns of care and outcomes for use of concurrent chemoradiotherapy over radiotherapy alone for anaplastic gliomas
Yeboa DN, Rutter CE, Park HS, Lester-Coll NH, Corso CD, Mancini BR, Bindra RS, Contessa J, Yu JB. Patterns of care and outcomes for use of concurrent chemoradiotherapy over radiotherapy alone for anaplastic gliomas. Radiotherapy And Oncology 2017, 125: 258-265. PMID: 29054377, DOI: 10.1016/j.radonc.2017.09.027.Peer-Reviewed Original ResearchConceptsUse of CCRTConcurrent chemoradiotherapyPatterns of careAnaplastic gliomasOverall survivalCox proportional hazards regression modelingProportional hazards regression modelingMultivariable logistic regression analysisConcurrent CRTNational Cancer DatabaseKaplan-Meier analysisLog-rank testLogistic regression analysisGrade III gliomasAdjusted hazardAdult patientsImproved survivalCancer DatabaseDesign cohortRadiotherapyPropensity scorePatientsGliomasChemoradiotherapyRegression modeling
2016
Hospital Volume and Outcomes of Robot-Assisted Lobectomies
Tchouta LN, Park HS, Boffa DJ, Blasberg JD, Detterbeck FC, Kim AW. Hospital Volume and Outcomes of Robot-Assisted Lobectomies. CHEST Journal 2016, 151: 329-339. PMID: 27687847, DOI: 10.1016/j.chest.2016.09.008.Peer-Reviewed Original ResearchMeSH KeywordsAgedCase-Control StudiesCohort StudiesDatabases, FactualFemaleHospital MortalityHospitals, High-VolumeHospitals, Low-VolumeHumansLength of StayLinear ModelsLogistic ModelsLungLung NeoplasmsMaleMiddle AgedMultivariate AnalysisPneumonectomyPostoperative ComplicationsRetrospective StudiesRobotic Surgical ProceduresThoracic Surgery, Video-AssistedTreatment OutcomeConceptsLength of stayLow-volume centersHospital volumeClinical impactHealth care system-related factorsShorter mean LOSUtilization Project National Inpatient Sample databaseVolume/outcome relationshipLong-term clinical impactMean LOSNational Inpatient Sample databaseShorter LOSVideo-assisted thoracoscopic surgeryHospital operative volumeHigh-volume hospitalsIncidence of complicationsHigher hospital volumeThoracoscopic surgery lobectomyAnnual case volumeSystem-related factorsOutcomes of interestLOS outcomesInfectious complicationsInpatient mortalityIndependent predictors
2015
Patients Selected for Definitive Concurrent Chemoradiation at High-volume Facilities Achieve Improved Survival in Stage III Non–Small-Cell Lung Cancer
Wang EH, Rutter CE, Corso CD, Decker RH, Wilson LD, Kim AW, Yu JB, Park HS. Patients Selected for Definitive Concurrent Chemoradiation at High-volume Facilities Achieve Improved Survival in Stage III Non–Small-Cell Lung Cancer. Journal Of Thoracic Oncology 2015, 10: 937-943. PMID: 25738221, DOI: 10.1097/jto.0000000000000519.Peer-Reviewed Original ResearchConceptsDefinitive concurrent chemoradiation therapyConcurrent chemoradiation therapyHigh-volume facilitiesNon-small cell lung cancerStage III NSCLC patientsCell lung cancerOverall survivalNSCLC patientsLung cancerStage III non-small cell lung cancerHigher Charlson-Deyo comorbidity scoresCharlson-Deyo comorbidity scoreNational Cancer Data BaseCox proportional hazards regressionFacility case volumeImproved overall survivalAdvanced nodal stageDefinitive concurrent chemoradiationKaplan-Meier analysisPopulation-based survivalMultivariable logistic regressionProportional hazards regressionRisk of deathIntensity-modulated radiotherapyAcademic affiliationRacial disparities in the use of SBRT for treating early-stage lung cancer
Corso CD, Park HS, Kim AW, Yu JB, Husain Z, Decker RH. Racial disparities in the use of SBRT for treating early-stage lung cancer. Lung Cancer 2015, 89: 133-138. PMID: 26051446, DOI: 10.1016/j.lungcan.2015.05.002.Peer-Reviewed Original ResearchConceptsStereotactic body radiotherapyUse of SBRTEarly-stage lung cancerBlack patientsExternal beam radiationWhite patientsAggressive therapyLung cancerRacial disparitiesNon-operative cohortNational Cancer DatabaseStage I NSCLCPrimary treatment modalitySurgical resection rateMultivariable logistic regressionPopulation-based studyPotential racial disparitiesInoperable candidatesSBRT useSBRT utilizationInoperable patientsResection rateSurgical resectionMultivariable analysisSurgical intervention
2012
Immortal Time Bias: A Frequently Unrecognized Threat to Validity in the Evaluation of Postoperative Radiotherapy
Park HS, Gross CP, Makarov DV, Yu JB. Immortal Time Bias: A Frequently Unrecognized Threat to Validity in the Evaluation of Postoperative Radiotherapy. International Journal Of Radiation Oncology • Biology • Physics 2012, 83: 1365-1373. PMID: 22342097, DOI: 10.1016/j.ijrobp.2011.10.025.Peer-Reviewed Original ResearchConceptsSequential landmark analysesPostoperative radiotherapyImmortal time biasLandmark analysisTumor typesEnd Results (SEER) databaseObservational cohort studyTime biasObservation cohortCohort studyHazard ratioProspective trialImproved survivalResults databaseConditional survivalRoutine useSurvivalApparent benefitRadiotherapyCohort
2009
Outcomes From 3144 Adrenalectomies in the United States: Which Matters More, Surgeon Volume or Specialty?
Park HS, Roman SA, Sosa JA. Outcomes From 3144 Adrenalectomies in the United States: Which Matters More, Surgeon Volume or Specialty? JAMA Surgery 2009, 144: 1060-1067. PMID: 19917944, DOI: 10.1001/archsurg.2009.191.Peer-Reviewed Original ResearchMeSH KeywordsAdrenal Gland NeoplasmsAdrenalectomyAdultAgedClinical CompetenceCohort StudiesFemaleFollow-Up StudiesHospital CostsHospital MortalityHumansLogistic ModelsMaleMiddle AgedMultivariate AnalysisOutcome Assessment, Health CarePractice Patterns, Physicians'ProbabilityRegistriesRetrospective StudiesRisk FactorsSpecializationSurvival RateTreatment OutcomeUnited StatesWorkloadConceptsHigh-volume surgeonsSurgeon volumeHospital volumeMore complicationsGeneral surgeonsUtilization Project Nationwide Inpatient SampleRetrospective cohort analysisNationwide Inpatient SampleLow-volume surgeonsPredictors of costsInpatient hospital costsTotal inpatient hospital costsHospital complicationsHospital lengthAdrenal volumeClinical characteristicsHospital factorsAdrenal diseaseIndependent predictorsLonger LOSPatient ageSurgeon specialtyInpatient SampleHospital costsLaparoscopic expertise